Search Articles

View query in Help articles search

Search Results (1 to 1 of 1 Results)

Download search results: CSV END BibTex RIS


Dexmedetomidine Versus Midazolam for End-of-Life Sedation and Agitation: Protocol for a Randomized Controlled Trial (The DREAMS Trial)

Dexmedetomidine Versus Midazolam for End-of-Life Sedation and Agitation: Protocol for a Randomized Controlled Trial (The DREAMS Trial)

In Australia, the injectable benzodiazepine, midazolam, is the typical first-line sedative used, which is in line with the position statement of the Australian and New Zealand Society of Palliative Medicine (ANZSPM) [5] and is consistent with recommendations from the European Association for Palliative Care (EAPC) framework for sedation at the end of life [6].

Benjamin Thomas, Greg Barclay, Wing-Shan Angela Lo, Judy Mullan, Kylie Mansfield

JMIR Res Protoc 2024;13:e55129